A new paper commenting on the initial paper that started this thread:
The Rust Hypothesis: Could Cheap Vitamin C Slow the Iron-Driven “Rusting” of an Aging Brain?
A commentary spotlights a landmark monkey study suggesting that high-dose vitamin C may blunt “ferro-aging” — an iron-and-lipid-peroxidation aging program driven by the enzyme ACSL4 — reversing molecular age markers and protecting the brain, liver, and metabolism. The authors are careful to stress the mechanism is unproven and the human evidence is, so far, discouraging.
Aging researchers have long suspected that the slow accumulation of iron in our tissues is not a bystander but a driver of decline. A new framework called “ferro-aging” now names a specific culprit: an enzyme called ACSL4, which loads cell membranes with the exact kind of fat most vulnerable to iron-catalyzed oxidative damage. Over decades, the theory goes, this produces a low-grade, smoldering version of the same chemistry that causes ferroptosis — a violent form of cell death — except spread out across years and organs, nudging cells toward senescence rather than sudden death.
The headline claim, drawn from a 40-month study in cynomolgus monkeys published in Cell Metabolism, is that ordinary vitamin C can interfere with this process. At high doses, vitamin C appears to dock into ACSL4 and dial down its activity, while separately mopping up free radicals and switching on the cell’s own antioxidant defense system (the Nrf2 pathway). Middle-aged monkeys given daily oral vitamin C for over three years showed lower tissue iron, less lipid damage, and — most strikingly — “younger” readings on multiple molecular aging clocks, with the brain’s immune cells clocking in nearly seven and a half years younger.
Here is where the commentary earns its credibility: it refuses to celebrate. The authors point out that the concentration of vitamin C needed to inhibit ACSL4 in a test tube (around 280 micromolar) is several times higher than what human blood can physiologically hold. They note that mutating the enzyme’s supposed vitamin-C binding site also cripples its normal function — meaning the “binding” evidence may be an artifact. They remind readers that decades of human vitamin C trials have shown essentially nothing for mortality, heart disease, or cancer. And they flag the real risk of kidney stones and, at megadoses, kidney injury.
The big idea is genuinely interesting: aging may have a shared, iron-lipid “master switch,” and a cheap, safe nutrient might partially flip it. But this is a monkey story wearing a human-hope costume. The mechanism is plausible, not confirmed; the benefits are real in Macaca fascicularis and entirely hypothetical in people.
The monkey dose was 30 mg/kg/day. Applying standard FDA allometric scaling (cynomolgus Km ≈ 12, human Km ≈ 37), the human-equivalent dose is roughly 30 × 12/37 ≈ 9.7 mg/kg/day, or about 680 mg/day for a 70 kg adult — a trivially achievable oral dose. So dose is not the barrier. The barrier is concentration at the target: oral vitamin C is under tight homeostatic control and plasma saturates around 70–90 µM regardless of how much you swallow, because absorption and renal reabsorption are saturable. The ACSL4-inhibition IC50 is ~280 µM — a 3–4x gap you physiologically cannot close with oral dosing. [Confidence: High]
Effect-size magnitude as reported (point estimates, no variance given): epigenetic age −5.91 years, transcriptomic age −5.67 years, microglial clock −7.39 years, in animals whose lifespan is ~25–30 years. Impressive on paper — but in monkeys, at supraphysiological tissue exposures that oral human dosing won’t reproduce.
Practical bottom line: Don’t megadose vitamin C for “ferro-aging.” Above ~1000 mg/day oral is linked to increased kidney stone risk in men, and IV megadosing has caused acute kidney injury. Meeting normal intake (75–90 mg/day RDA, or ~200 mg from a produce-rich diet for tissue saturation) remains reasonable. Managing genuine iron overload — donating blood if ferritin is high, not over-supplementing iron — is a more mechanistically coherent “ferro-aging” lever than vitamin C.
Source:
- Open Access Paper: Vitamin C, ACSL4, and Ferro-Aging: Mechanistic Insights and Translational Perspectives from Primate Studies
- Institution: Xinjiang Medical University (Cancer Research Institute, The Third Teaching Hospital / Affiliated Cancer Hospital; and School of Stomatology), Urumqi — with co-authors from Renmin Hospital of Wuhan University. A private entity, “Sonnig Biomedical Studio, Urumqi,” is also listed as an affiliation.
- Country: China.
- Journal: Aging and Disease (the commentary). Primary data source: Cell Metabolism.